Andaris renames longlife ultrasound agent:
This article was originally published in Clinica
Andaris, a private UK company, has renamed its long-lasting ultrasound contrast imaging agent, formerly called Quantison Depot. The product, now in preclinical testing, is renamed Myomap. It is claimed Myomap will offer continuous or repeated real-time, high-definition, ultrasound imaging of the myocardium over several hours. Andaris also produces an intravenous diagnostic imaging agent called Quantison, which is in phase II trials, and the name change reflects the need to differentiate the products.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.